Clinical Report: A New Route to Lymphoma Diagnosis

Overview

Enhance the significance of findings in relation to existing diagnostic methods.

Background

Burkitt’s lymphoma (BL) is an aggressive cancer predominantly affecting children in sub-Saharan Africa, with a strong association to EBV infection. Traditional diagnostic methods, including tissue biopsy and immunohistochemistry, can be hindered by accessibility issues, leading to delays in diagnosis and treatment. The exploration of liquid biopsy techniques offers a potential solution to these challenges.

Data Highlights

Key Findings

• The liquid biopsy assay demonstrated a sensitivity of 0.86 and specificity of 0.95 for diagnosing BL.
• Median turnaround time for liquid biopsy results was 6.5 days compared to 46.8 days for tissue biopsy.
• Liquid biopsy identified more than half of the patients later confirmed to have BL at the first multidisciplinary team review.
• Combining multiple molecular markers improved diagnostic accuracy beyond EBV DNA levels alone.
• Liquid biopsy may complement tissue-based methods, particularly in regions with limited histopathology services.

Clinical Implications

The findings suggest that liquid biopsy can serve as a rapid and effective diagnostic tool for BL, potentially expediting treatment initiation in resource-limited settings. Clinicians should consider integrating liquid biopsy results into their diagnostic workflows, especially when traditional methods are not readily available.

Conclusion

Liquid biopsy represents a promising advancement in the diagnosis of EBV-positive Burkitt’s lymphoma, offering quicker results and the potential for improved patient outcomes in endemic regions.

Related Resources & Content

1. Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas | Nature Medicine, 2026
2. My 50 Years in Lymphoma: Lessons Learned? | The ASCO Post, 2025
3. The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer | Fox Chase Cancer Center
4. Important Briefs: Lymphoma Research on Improved Chemotherapy, Biomarker Associations, and Stem Cell Transplant Approaches | The ASCO Post, 2011
5. Acta Neuropathologica — Accelerated Diagnosis of Brain Lymphoma via Nanopore Sequencing of Cytology-Negative Cerebrospinal Fluid
6. Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas | Nature Medicine
7. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial - ScienceDirect